Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
企業コードMOLN
会社名Molecular Partners AG
上場日Oct 22, 2014
最高経営責任者「CEO」Dr. Patrick Amstutz, Ph.D.
従業員数159
証券種類Ordinary Share
決算期末Oct 22
本社所在地Wagistrasse 14
都市SCHLIEREN
証券取引所SIX Swiss Exchange
国Switzerland
郵便番号8952
電話番号41447557700
ウェブサイトhttps://www.molecularpartners.com/
企業コードMOLN
上場日Oct 22, 2014
最高経営責任者「CEO」Dr. Patrick Amstutz, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし